Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204186940> ?p ?o ?g. }
- W3204186940 endingPage "4593" @default.
- W3204186940 startingPage "4593" @default.
- W3204186940 abstract "Multiple myeloma (MM) patients eventually develop multi-drug-resistant disease with poor survival. Hence, the development of novel treatment strategies is of great importance. Recently, different classes of immunotherapeutic agents have shown great promise in heavily pre-treated MM, including T cell-redirecting bispecific antibodies (BsAbs). These BsAbs simultaneously interact with CD3 on effector T cells and a tumor-associated antigen on MM cells, resulting in redirection of T cells to MM cells. This leads to the formation of an immunologic synapse, the release of granzymes/perforins, and subsequent tumor cell lysis. Several ongoing phase 1 studies show substantial activity and a favorable toxicity profile with BCMA-, GPRC5D-, or FcRH5-targeting BsAbs in heavily pre-treated MM patients. Resistance mechanisms against BsAbs include tumor-related features, T cell characteristics, and impact of components of the immunosuppressive tumor microenvironment. Various clinical trials are currently evaluating combination therapy with a BsAb and another agent, such as a CD38-targeting antibody or an immunomodulatory drug (e.g., pomalidomide), to further improve response depth and duration. Additionally, the combination of two BsAbs, simultaneously targeting two different antigens to prevent antigen escape, is being explored in clinical studies. The evaluation of BsAbs in earlier lines of therapy, including newly diagnosed MM, is warranted, based on the efficacy of BsAbs in advanced MM." @default.
- W3204186940 created "2021-10-11" @default.
- W3204186940 creator A5001347837 @default.
- W3204186940 creator A5042853155 @default.
- W3204186940 creator A5058437667 @default.
- W3204186940 creator A5060077460 @default.
- W3204186940 creator A5069712875 @default.
- W3204186940 creator A5080836916 @default.
- W3204186940 creator A5083385949 @default.
- W3204186940 date "2021-10-06" @default.
- W3204186940 modified "2023-09-27" @default.
- W3204186940 title "Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma" @default.
- W3204186940 cites W1494138467 @default.
- W3204186940 cites W1661103064 @default.
- W3204186940 cites W1832162035 @default.
- W3204186940 cites W1902692042 @default.
- W3204186940 cites W1978667353 @default.
- W3204186940 cites W1996815863 @default.
- W3204186940 cites W2002048624 @default.
- W3204186940 cites W2009626568 @default.
- W3204186940 cites W2019396853 @default.
- W3204186940 cites W2020298011 @default.
- W3204186940 cites W2051426298 @default.
- W3204186940 cites W2055342376 @default.
- W3204186940 cites W2067577146 @default.
- W3204186940 cites W2069282346 @default.
- W3204186940 cites W2071929715 @default.
- W3204186940 cites W2083494119 @default.
- W3204186940 cites W2112506009 @default.
- W3204186940 cites W2114551673 @default.
- W3204186940 cites W2136374191 @default.
- W3204186940 cites W2136453261 @default.
- W3204186940 cites W2145345130 @default.
- W3204186940 cites W2146480092 @default.
- W3204186940 cites W2151536565 @default.
- W3204186940 cites W2151675691 @default.
- W3204186940 cites W2164793815 @default.
- W3204186940 cites W2184270030 @default.
- W3204186940 cites W2201190784 @default.
- W3204186940 cites W2361098417 @default.
- W3204186940 cites W2402003835 @default.
- W3204186940 cites W2494994085 @default.
- W3204186940 cites W2528329272 @default.
- W3204186940 cites W2561836860 @default.
- W3204186940 cites W2562243521 @default.
- W3204186940 cites W2571138221 @default.
- W3204186940 cites W2580453358 @default.
- W3204186940 cites W2591709377 @default.
- W3204186940 cites W2592173429 @default.
- W3204186940 cites W2626992247 @default.
- W3204186940 cites W2765695907 @default.
- W3204186940 cites W2767256995 @default.
- W3204186940 cites W2767440408 @default.
- W3204186940 cites W2791775923 @default.
- W3204186940 cites W2807110328 @default.
- W3204186940 cites W2886837533 @default.
- W3204186940 cites W2888063816 @default.
- W3204186940 cites W2914635378 @default.
- W3204186940 cites W2923396001 @default.
- W3204186940 cites W2924802726 @default.
- W3204186940 cites W2929340554 @default.
- W3204186940 cites W2953662185 @default.
- W3204186940 cites W2960114219 @default.
- W3204186940 cites W2969569086 @default.
- W3204186940 cites W2980891654 @default.
- W3204186940 cites W2984499287 @default.
- W3204186940 cites W2988512835 @default.
- W3204186940 cites W2991132415 @default.
- W3204186940 cites W2995373288 @default.
- W3204186940 cites W2997301227 @default.
- W3204186940 cites W3001702717 @default.
- W3204186940 cites W3004303031 @default.
- W3204186940 cites W3005994291 @default.
- W3204186940 cites W3017098331 @default.
- W3204186940 cites W3040997370 @default.
- W3204186940 cites W3044843687 @default.
- W3204186940 cites W3082995442 @default.
- W3204186940 cites W3083011336 @default.
- W3204186940 cites W3086013181 @default.
- W3204186940 cites W3087111554 @default.
- W3204186940 cites W3087621471 @default.
- W3204186940 cites W3097214754 @default.
- W3204186940 cites W3101609280 @default.
- W3204186940 cites W3108432884 @default.
- W3204186940 cites W3133229959 @default.
- W3204186940 cites W3133851812 @default.
- W3204186940 cites W3154427589 @default.
- W3204186940 cites W3158345122 @default.
- W3204186940 cites W3158660900 @default.
- W3204186940 cites W3164922049 @default.
- W3204186940 cites W3167555080 @default.
- W3204186940 cites W3168029500 @default.
- W3204186940 cites W3168407158 @default.
- W3204186940 cites W3169689223 @default.
- W3204186940 cites W3188071931 @default.
- W3204186940 cites W4211058750 @default.
- W3204186940 cites W4230744147 @default.
- W3204186940 cites W4231230255 @default.